Reference

Comparisons

Both sides get the same rows, the same sourcing, and no verdict. What we can tell you is how they differ; which one belongs in your situation is a conversation for you and a clinician.

Semaglutide vs liraglutide

Same receptor, same drug class, one generation apart. One is a weekly injection and produced about twice the weight reduction of the other, which is a daily one.

BPC-157 vs Thymosin Beta-4

The two halves of the repair pairing, compared instead of combined. This is also where the TB-500 naming confusion does the most damage.

Ipamorelin vs GHRP-2

Two ghrelin-receptor secretagogues doing the same job. Selectivity is what separates them: one raises growth hormone and little else, the other raises several things at once.

Retatrutide vs semaglutide

One receptor against three, and a finished approval against a trial programme still running. The largest reported effect in the class, set beside the most established one.

GHK-Cu vs AHK-Cu

Two copper peptides sold for different tissue. Both carry copper, and that is why running them together is a question, not a default.

Sermorelin vs CJC-1295

Two GHRH analogues on the same receptor. How long each survives in the body is the difference, and it changes both the schedule and the shape of what comes out.

Tesamorelin vs HGH

Ask the body to release its own growth hormone, or supply it from outside. The choice decides how much say the body's own feedback still has.

5-Amino-1MQ vs MOTS-c

Two metabolic compounds approached from opposite ends: an oral small molecule that inhibits an enzyme, and a mitochondrial peptide. Almost no human data between them.

Semaglutide vs cagrilintide

Two different satiety pathways, usually discussed as a pair rather than a choice. One is an approved drug on its own; the other is mostly studied alongside it.

Epitalon vs NAD+

Two longevity compounds with problems of completely different kinds. One has a replication problem. The other has a delivery problem.

Tirzepatide vs survodutide

Two dual agonists that picked different second receptors, GIP in one case and glucagon in the other, and that sit at very different stages of evidence.

MK-677 vs HGH

An oral secretagogue against injected growth hormone. Cheaper, needle-free and indirect on one side. The hormone itself, dosed in IU, on the other.

Semaglutide vs tirzepatide

Both are once-weekly incretin agonists approved for weight management. The difference is how many receptors each one acts on, and what that does to the dosing scale.

BPC-157 vs TB-500

Two research peptides discussed for tissue repair. Both rest on animal evidence, and they differ in proposed mechanism and in dose scale.

CJC-1295 vs ipamorelin

The most compared pair in this category, and the comparison is slightly wrong-headed: they act on different receptors and are usually run together rather than chosen between.

Tesamorelin vs CJC-1295

Two GHRH analogues acting on the same receptor, separated by the largest evidence gap on this site: one completed a phase 3 programme and holds an approval, the other has neither.

Same receptor, opposite shapes. One is an oral small molecule producing sustained elevation; the other is an injected peptide producing a short pulse. Only one of them has a trial that was stopped early.

Tirzepatide vs retatrutide

Two and three receptors respectively. Retatrutide reported the larger weight reduction; tirzepatide has a completed phase 3 programme and an approval. This is a different kind of claim.

NAD+ vs Epitalon

Two longevity compounds with very different problems: one has a delivery problem, the other has a replication problem.